Skip to main content
Download PDF

Regulation of YKL-40 expression by corticosteroids: effect on pro-inflammatory macrophages in vitro and its modulation in COPD in vivo

Respiratory Research volume 16, Article number: 154 (2015) Cite this article

Abstract

Background

Macrophages constitute a heterogeneous cell population with pro- (MΦ1) and anti-inflammatory (MΦ2) cells. The soluble chitinase-like-protein YKL-40 is expressed in macrophages and various other cell types, and has been linked to a variety of inflammatory diseases, including COPD. Dexamethasone strongly reduces YKL-40 expression in peripheral blood mononuclear cells (PBMC) in vitro. We hypothesized that: a) YKL-40 is differentially expressed by MΦ1 and MΦ2, b) is decreased by corticosteroids and c) that long-term treatment with inhaled corticosteroids (ICS) affects YKL-40 levels in serum and sputum of COPD patients.

Methods

Monocytes of healthy subjects were cultured in vitro for 7 days with either GM-CSF or M-CSF (for MΦ1 and MΦ2, respectively) and stimulated for 24 h with LPS, TNFα, or oncostatin M (OSM). MΦ1 and MΦ2 differentiation was assessed by measuring secretion of IL-12p40 and IL-10, respectively. YKL-40 expression in macrophages was measured by quantitative RT-PCR (qPCR) and ELISA; serum and sputum YKL-40 levels were analyzed by ELISA.

Results

Pro-inflammatory MΦ1 cells secreted significantly more YKL-40 than MΦ2, which was independent of stimulation with LPS, TNFα or OSM (p < 0.001) and confirmed by qPCR. Dexamethasone dose-dependently and significantly inhibited YKL-40 protein and mRNA levels in MΦ1. Serum YKL-40 levels of COPD patients were significantly higher than sputum YKL-40 levels but were not significantly changed by ICS treatment.

Conclusions

YKL-40 secretion from MΦ1 cells is higher than from MΦ2 cells and is unaffected by further stimulation with pro-inflammatory agents. Furthermore, YKL-40 release from cultured monocyte-derived macrophages is inhibited by dexamethasone especially in MΦ1, but ICS treatment did not change YKL-40 serum and sputum levels in COPD. These results indicate that YKL-40 expression could be used as a marker for MΦ1 macrophages in vitro, but not for monitoring the effect of ICS in COPD.

Trial registration

ClinicalTrials.gov, registration number: NCT00158847

Background

YKL-40 (or chitinase 3-like-1 [CHI3L1], breast regression protein [BRP]-39 or human cartilage glycoprotein-39 [HC gp-39]) is a chitinase-like protein which is found in humans [1]. It is expressed by various cell types, including neutrophils and macrophages [2–4], while macrophages have been identified as its main cellular source [2, 5]. Monocytes do not express YKL-40, and YKL-40 expression appears to be associated with later stages of macrophage differentiation [2, 6]. Although its biological function is largely unknown, YKL-40 has been suggested to play a major role in a variety of processes, including epithelial-mesenchymal transition, migration and proliferation of (malignant) cells, angiogenesis, tissue remodeling and inflammation [7–9]. Furthermore, YKL-40 has been implicated in several acute and chronic inflammatory diseases, including asthma and COPD [10, 11]. Several studies have shown that YKL-40 levels are higher in sputum and serum of COPD patients compared to asymptomatic smokers [12, 13].

These data suggest that macrophages may also be a major source of YKL-40 in inflammatory lung diseases such as COPD, a disease in which macrophages play an important role [14]. It is however unknown whether YKL-40 expression is restricted to a subset of macrophages. This is a relevant question, since macrophages constitute heterogeneous cell populations with various functions. Pro-inflammatory, or classically activated macrophages (type I, MΦ1), show pro-inflammatory properties by secreting pro-inflammatory cytokines such as interleukin (IL)-12, have antigen presenting capacity and promote Th1 immunity. In contrast, anti-inflammatory, or alternatively activated macrophages (type II, MΦ2), demonstrate anti-inflammatory characteristics with expression and secretion of anti-inflammatory cytokines, such as IL-10 and promote development of regulatory T cells [15]. Furthermore, Di Rosa et al. observed higher expression of YKL-40 in monocyte-derived MΦ1 [16].

Dexamethasone strongly suppresses YKL-40 expression in cultured monocyte-derived macrophages [17]. In line with these findings, rheumatoid arthritis patients treated with methotrexate and prednisolone had lower serum YKL-40 concentrations compared to patients treated without prednisolone [18]. However, it is unknown if YKL-40 levels are influenced by treatment with inhaled corticosteroids (ICS) in COPD and could therefore be used to monitor treatment response. Furthermore, it is not known whether modulation by steroids is a direct genomic anti-inflammatory effect or due to e.g. epigenetic mechanisms [19–22].

Based on these observations we hypothesized that YKL-40 expression is directed by macrophage polarization, with a higher expression in monocyte-derived MΦ1 compared to MΦ2. Furthermore, we hypothesized that steroids decrease YKL-40 secretion and expression in MΦ1 and that YKL-40 in serum and sputum of COPD patients is decreased by treatment with ICS. The results from this study show that monocyte-derived MΦ1 secrete and express more YKL-40 than MΦ2. YKL-40 expression by cultured MΦ1 cells is steroid sensitive as its production is decreased by dexamethasone. Finally, YKL-40 levels in sputum and serum do not differ between COPD patients treated for 30 months with ICS or placebo.

Methods

Cell culture

Monocytes were isolated from buffy coats of healthy blood donors (Sanquin Blood Bank, Leiden, The Netherlands) using anti-CD14 microbeads (Miltenyi Biotec, Auburn, CA, USA) according to the manufacturer’s protocol. MΦ1 and MΦ2 were derived as described previously [23, 24]. Briefly, cells were cultured for six days in RPMI 1640 medium in 48 well plates (Invitrogen, Life Technologies, Bleiswijk, The Netherlands) containing 10 % fetal calf serum (FCS, Invitrogen), 2 mM L-glutamine, 100U/ml penicillin and 100 μg/ml streptomycin (all Bio Whittaker, Walkersville, MD, USA) at 37 °C in 5 % CO2 atmosphere with either GM-CSF (5 ng/ml, Invitrogen) or M-CSF (50 ng/ml, R&D Systems, Minneapolis, MN, USA) to obtain MΦ1 and MΦ2, respectively [13, 14]. Differentiated macrophages were stimulated with the pro-inflammatory stimuli lipopolysaccharide (LPS, from Pseudomonas aeruginosa, 100 ng/ml, Sigma-Aldrich, St. Louis, MO, USA), TNF-α (10 ng/ml, Peprotech, Rocky Hill, NJ, USA) or oncostatin M (OSM, 100 ng/ml, R&D Systems) for 24 h. Dexamethasone (0.1, 0.3 and 1nM, Sigma) was added during differentiation at day 0, 3 and/or day 7. The demethylating agent 5-AZA-2’-deoxycytidine (5-AZA, 0.1, 1 and 10 μM, Sigma) was added during differentiation. Every day 100 μl per well was removed and replaced by fresh medium containing growth factors and 5-AZA.

GLUCOLD study

Serum and sputum supernatants were obtained from patients with moderate to severe COPD who participated in the GLUCOLD (Groningen and Leiden Universities Corticosteroids in Obstructive Lung Disease) study [25]. Patients were steroid-naive at baseline and were subsequently randomized to one of four inhaled treatments, all twice daily: 6- or 30-month fluticasone propionate dry-powder inhaler (500 μg, group 1 and 2, respectively), 30-month fluticasone with salmeterol (500/50 μg, group 3) or 30-month placebo (group 4). In this mechanistic study, we only used data from the compliant patients (≥70 % of the prescribed dose of treatment) of groups 2 and 3 combined to increase power, and group 4. At baseline and after 30 months of treatment, serum and sputum samples were collected. Sputum induction and processing were performed as previously described [26, 27]. Cell free supernatants of serum and sputum were stored at −80 °C. The ethics committees of Leiden University Medical Center and University Medical Center Groningen approved the study and all patients provided written informed consent.

Enzyme-linked Immunosorbent Assay (ELISA)

Commercially available ELISA kits were used to detect IL-12p40 (IL-12/IL-23p40, R&D Systems; sensitivity 62.5 pg/ml) and IL-10 (Sanquin, Amsterdam, The Netherlands; sensitivity 4.1 pg/ml), to confirm that the monocytes were adequately differentiated towards MΦ1 and MΦ2, respectively (Fig. 1a). YKL-40 ELISA (R&D Systems; sensitivity 16 pg/ml [10]) was performed on cell culture supernatant, serum and sputum supernatant. The absorbance was measured at 450 nm using a Microplate reader (model 680; Bio-Rad, Hercules, CA, USA) and Microplate Manager software (version 5.2.1, Bio-Rad).

Fig. 1
figure 1

Characterization of differentiated MΦ1 and MΦ2. a: IL-12p40 (left panel) and IL-10 (right panel) in supernatants of MΦ1 and MΦ2, respectively, stimulated with LPS for 24 h. Data represent means with SEM of 6 donors, ** p < 0.01 or *** p < 0.001 between MΦ1 and MΦ2. b: Flow cytometry analysis for CD68, CD14 and CD163 (left, middle and right panel, respectively) for MΦ1 and MΦ2 (upper and lower panel, respectively)

Full size image

Flow cytometry

Cell surface markers were assessed by standard flow cytometry using a FACS Calibur cytometer (Becton and Dickinson, La Jolla, CA, USA) and CellQuest Pro software after staining with specific APC-conjugated CD163 and CD14 (both BD Biosciences/Pharmingen (Temse, Belgium), FITC-conjugated CD68 (eBioscience, Vienna, Austria) and/or goat-anti-human YKL-40 (R&D systems) detected by Alexa Fluor 594 F(ab’)2 fragment of goat anti-mouse (Invitrogen) as secondary antibody. Cells were incubated with the antibodies for 30 min on ice in PBS containing 0.5 % BSA (w/v) and 0.2 % sodium azide (w/v) (both Sigma). After fixation with Cytofix/Cytoperm buffer, intracellular staining was performed in Perm/Wash buffer (both BD Biosciences). Flow cytometric analysis confirmed that the differentiated monocytes were CD14+ and CD68+, and that the majority of MΦ2 were CD163+ (Fig. 1b). Therefore, we concluded that the monocytes were properly differentiated into MΦ1 and MΦ2 cells.

Immunofluorescence staining

YKL-40 and CD68 expression in sputum cytospins was demonstrated using immunofluorescence. Cytospins were fixed in 4 % formaldehyde in PBS for 30 min, followed by antigen retrieval in citrate solution pH6.0 (DAKO, Glostrup, Denmark) for 30 min and cooled on ice. The primary antibodies goat-anti-human YKL-40 (R&D systems, dilution 1:25) and mouse-anti-human CD68 (clone PG-M1, DAKO, dilution 1:50), diluted in PBS/1 % BSA (w/v) were incubated together overnight. Alexa Fluor568 donkey-anti-goat and Alexa Fluor 488 donkey-anti-mouse (Invitrogen, Eugene, Oregon, USA, dilution of both 1:200) were incubated in a dark environment for 30 min. The cytospins were covered with Vectashield with DAPI (Vector Laboratories, Inc. Burlingame, CA, USA). Photographs were taken with a confocal microscope.

Quantitative reverse-transcriptase polymerase chain reaction (qPCR)

RNA was isolated using Qiagen RNeasy mini kit (Qiagen, Venlo, The Netherlands) and cDNA was synthesized in equal amounts per experiment. Quantitative reverse-transcriptase polymerase chain reaction (qPCR) was performed with the primers for YKL-40 and LL-37 as presented in Table 1. QPCR was performed on the iCycler PCR device using iQ SYBR Green Supermix (Bio-Rad) for 40 cycles at 58 °C. Relative mRNA concentrations of ACTB and ATP5B (GeNorm, PrimerDesign Ltd., Southampton, UK) were used as housekeeping genes for human genes.

Table 1 Primer pairs used for quantitative reverse-transcriptase polymerase chain reaction (qPCR)
Full size table

Statistical analysis

Differences within one cell type and between cell types were analyzed by one-way and two-way ANOVA, respectively. Paired and unpaired tests were used for evaluating YKL-40 levels in serum and sputum within and between treatments, respectively, using only data from subjects with availability of samples from both baseline and 30 months. Statistical analysis was performed with SPSS 22.0 software (SPSS Inc., Chicago, IL). Data are presented as means with standard error of the mean (SEM) for in vitro experiments and means with standard deviations (SD) for serum and sputum samples. Differences at p-values ≤0.05 were inferred as statistically significant.

Results

MΦ1 produce more YKL-40 compared to MΦ2

Secretion of YKL-40 by MΦ1 was markedly higher compared to MΦ2 (p < 0.001) and not further increased by stimulation for 24 h with 100 ng/ml LPS compared to medium (p < 0.001; Fig. 2a, left panel). qPCR confirmed these results, i.e. MΦ1 express more YKL-40 than MΦ2 with and without LPS stimulation (10-fold higher in MΦ1 vs MΦ2, p < 0.001; Fig. 2a, right panel), with a trend towards more YKL-40 expression in LPS-stimulated MΦ1 (p < 0.1). Flow cytometry analysis also showed that MΦ1 cells express more YKL-40 compared to MΦ2 (Fig. 2b). In addition, MΦ1 secreted more YKL-40 compared to MΦ2 which was irrespective of further stimulation with TNF-α, and OSM for 24 or 48 h, respectively (all p < 0.001, Fig. 2c). Immunofluorescence staining showed that only a minority of macrophages in sputum of COPD patients was positive for YKL-40 as shown by co-staining with CD68 (Fig. 2d).

Fig. 2
figure 2

MΦ1 produce more YKL-40 compared to MΦ2. a: YKL-40 secretion measured by ELISA (left panel, 6 donors) and mRNA levels (normalized expression, right panel, 5 donors) in MΦ1 and MΦ2 after medium and LPS stimulation for 24 h. * p < 0.05 or *** p < 0.001 between MΦ1 and MΦ2. b: Flow cytometry analysis of MΦ1 and MΦ2 with and without anti-YKL-40 and secondary antibody. Left panel: MΦ1 with secondary antibody (purple) and MΦ1 with anti-YKL-40 and secondary antibody (black); middle panel: MΦ2 with secondary antibody alone (purple) and MΦ2 with anti-YKL-40 and secondary antibody (black); right panel: MΦ1 and anti-YKL-40 with secondary antibody (red) and MΦ2 and anti-YKL-40 with secondary antibody (blue). c: YKL-40 secretion in MΦ1 and MΦ2 after 24 and 48 h of stimulation with medium, LPS, TNFα and oncostatin M (OSM). Data represent mean and SEM of 4 and 3 donors (24 and 48 h, respectively). *: p < 0.001 between MΦ1 and MΦ2 for corresponding stimulus and time. $: p < 0.001 between corresponding stimulus at different time points. d: Immunofluorescence staining on sputum cytospin of a COPD patient (blue: DAPI; red: YKL-40; green: CD68)

Full size image

YKL-40 expression is inhibited by dexamethasone

To investigate the effect of steroids on macrophage YKL-40 expression, we first assessed its effect on expression of the MΦ1 and MΦ2 markers IL-12p40 and IL-10. Whereas dexamethasone did not affect IL-10 secretion, it inhibited IL-12p40 secretion, especially when added at day 0 (Fig. 3a and b, respectively). In line with these findings, dexamethasone also dose-dependently inhibited YKL-40 expression and secretion mainly in MΦ1 (Fig. 4a and b, respectively). Again this effect was most pronounced when dexamethasone was added from the start of the differentiation at day 0 (Fig. 4a and b, left panel). Adding dexamethasone at later time points (day 3 or day 7) showed a trend for lower YKL-40 expression and secretion (Fig. 4a and b, middle and right panel, respectively), but failed to reach significance.

Fig. 3
figure 3

IL-12p40 secretion is dose-dependently inhibited by dexamethasone when added on day 0. IL-10 and IL-12p40 secretion with addition of dexamethasone at day 0, 3 and 7 of differentiation (0.1, 0.3 and 1nM) (a and b, left, middle and right panel, respectively). Data represent means and SEM (n = 3 donors). * p ≤ 0.05, ** p < 0.01 or *** p < 0.001: between MΦ1 to MΦ2 with corresponding stimulus. $ p ≤ 0.05 or $ p < 0.001 between MΦ1 at different concentrations of dexamethasone

Full size image
Fig. 4
figure 4

YKL-40 expression and protein secretion is inhibited by dexamethasone. YKL-40 mRNA levels (normalized expression) and YKL-40 protein secretion (a and b, respectively) in MΦ1 and MΦ2 with addition of dexamethasone at day 0, 3 and 7 of differentiation (0.1, 0.3 and 1nM) (left, middle and right panel, respectively). LL-37 mRNA levels (normalized expression) after 0, 3 and 7 days of differentiation with dexamethasone (0.1, 0.3 and 1nM) (c left, middle and right panel, respectively). Data represent means and SEM (n = 3 donors). * p ≤ 0.05, ** p < 0.01 or *** p < 0.001 compared to MΦ2 with corresponding stimulus. $ = p ≤ 0.05, $$ p < 0.01 or $$$ p < 0.001 compared to corresponding unstimulated cells. ##: p < 0.01 or ### p < 0.001 compared to corresponding LPS stimulated cells

Full size image

We have previously demonstrated that the human cathelicidin antimicrobial peptide hCAP/LL-37 directs macrophage differentiation towards MΦ1 cells [28]. In the course of the latter studies we also noted that hCAP18/LL-37 is preferentially expressed in MΦ1 cells (unpublished results). In the present study, we therefore used LL-37 expression for a comparison with YKL-40 expression. In line with the findings for IL-12p40 and YKL-40, the expression of LL-37 was also dose-dependently reduced by increasing doses of dexamethasone when added on day 0, but not on day 3 or day 7 (Fig. 4c).

Collectively these data indicate that dexamethasone inhibits YKL-40 expression, but that this effect is most likely explained by a more generic effect on MΦ1 development and is not selective for YKL-40 expression.

YKL-40 expression is not affected by the demethylating agent 5-AZA

Epigenetic mechanisms may contribute to CHI3L1 expression. This is supported by the finding of a single-nucleotide polymorphism (SNP) localized near the CpG island in the promoter region of the CHI3L1 gene, which is associated with YKL-40 expression [19, 20]. To evaluate whether YKL-40 expression in monocyte-derived macrophages is influenced by the methylation status of the CHI3L1 gene, macrophages were generated in the presence of the demethylating agent 5-AZA. We first observed that 5-AZA inhibited IL-12p40 secretion, and to a smaller extent also IL-10 secretion (Fig. 5a and b, respectively). In contrast, YKL-40 protein secretion and expression was not significantly affected by 5-AZA, although it needs to be noted that the highest concentration resulted in cell toxicity (Fig. 5c and d, respectively).

Fig. 5
figure 5

YKL-40 protein secretion and mRNA expression is inhibited by the demethylating agent 5AZA. IL-10 and IL-12p40 secretion after stimulation with 5-AZA (concentration 0.1, 1 and 10 μM) (a and b, respectively). YKL-40 protein secretion and mRNA expression in MΦ1 and MΦ2 after culturing with 5-AZA (concentration 0.1, 0.3 and 1nM) (c and d, respectively). Differentiated cells are stimulated with 100 ng/ml LPS for 24 h. Data represent mean and SEM (n = 3 donors). * p ≤ 0.05, ** p < 0.01 or *** p < 0.001 compared to MΦ2 with corresponding stimulus. # p ≤ 0.05, ##: p < 0.01 or ### p < 0.001 compared to corresponding LPS stimulated cells

Full size image

YKL-40 levels in serum and sputum of COPD patients are not changed by treatment with inhaled corticosteroids

We next used samples of the GLUCOLD study to investigate the effects of ICS treatment on serum and sputum YKL-40 levels in COPD patients. Baseline characteristics between the group of moderate-to-severe COPD patients treated with ICS and placebo were not significantly different as shown in Table 2. Of the 75 compliant patients, 70 serum samples and 59 induced sputum samples at baseline were available and suitable for analysis. Serum YKL-40 levels at baseline were significantly higher compared to sputum levels at baseline (respectively median 71 ng/ml versus 29 ng/ml, p < 0.001). ICS treatment did not significantly change YKL-40 levels in serum and sputum compared to placebo (both p > 0.05; Fig. 6).

Table 2 Patient characteristics of compliant patients at baseline of the GLUCOLD study
Full size table
Fig. 6
figure 6

Sputum and serum YKL-40 protein levels of COPD patients before and after ICS treatment. YKL-40 levels in sputum and serum at baseline (0) and after 30 months (30 m) of inhaled corticosteroids (ICS) and placebo. For comparison of the levels between baseline and 30 months, we only included patients from whom samples were available at both time points (paired data). Each dot represent a single patient, red horizontal bars represent medians

Full size image

Discussion

This study shows that secretion and expression of YKL-40, a chitinase-like protein, is higher in in vitro generated monocyte-derived MΦ1 than in MΦ2, and that YKL-40 expression is not further increased upon stimulation with several pro-inflammatory stimuli. In addition, YKL-40 release in vitro is strongly inhibited by dexamethasone especially in MΦ1, most likely due to an effect on differentiation. Addition of the demethylating agent 5-AZA did not significantly decrease YKL-40 release, but did decrease IL-12p40 production by MΦ1 and to a smaller extent IL-10 production by MΦ2 cells. YKL-40 levels in serum were significantly higher in serum than in sputum of COPD patients. Treatment of these patients for 2.5 years with inhaled corticosteroids did not significantly change serum and sputum YKL-40 levels compared to placebo. These results suggest that YKL-40 is a promising pro-inflammatory marker in in vitro cultured pro-inflammatory macrophages, but is less suitable for monitoring in vivo effect of treatment with steroids on YKL-40 in serum and sputum of COPD patients.

We show that YKL-40 is a novel marker of in vitro cultured monocyte-derived MΦ1, which is independent of LPS, OSM and TNFα. This is an important observation, since many established MΦ1 markers require additional stimulation to induce expression. Our data confirm and extend previous results [16, 17, 29], reporting higher CHI3L1 expression in classically activated macrophages compared to alternatively activated macrophages. In the latter studies, in contrast to our study, interferon-gamma (IFN-γ) and IL-4 were used for MΦ1 and MΦ2 polarization, respectively [16, 17]. We extended these data by differentiating monocytes with GM-CSF and M-CSF into MΦ1 and MΦ2, respectively, and explored the effect of further stimulation after differentiation with several pro-inflammatory stimuli. We found that dexamethasone efficiently suppressed YKL-40 expression and secretion in MΦ1, but that this was mainly explained by an inhibitory effect of dexamethasone on MΦ1differentiation, thus extending previous results [17].

We found that YKL-40 levels in serum were higher than in sputum of COPD patients. Serum YKL-40 levels of our group of patients were comparable with previous studies [13, 30, 31]. However, sputum YKL-40 levels with sputum processed using the whole sample method, were considerably lower than in studies using the selected plug method [12]. This is most likely due to dilution which is inherent to the whole sample method. After long-term treatment with ICS, we did not detect a significant change in YKL-40 levels in serum and sputum compared to placebo. To our knowledge, this is the first study that evaluates the long-term effect of ICS in serum and sputum YKL-40 levels of COPD patients. Therefore, this study presents new in vitro and in vivo data that may help to provide insight in the function of YKL-40.

The mechanisms that regulate YKL-40 expression in health and disease are partly understood. It has been demonstrated that YKL-40 expression is absent in monocytes, and markedly induced during macrophage differentiation, especially during the later stages of differentiation [2]. Promotor analysis of the CHI3L1 gene revealed that especially Sp1, an ubiquitous transcription factor, is important for CHI3L1 gene expression [6]. Possibly epigenetic mechanisms also contribute to CHI3L1 expression. This is supported by the finding of a SNP localized near the CpG island in the promoter region of the CHI3L1 gene, which is associated with YKL-40 expression [19, 20, 32]. Furthermore, hypomethylation of the CHI3L1 gene in rheumatoid arthritis is associated with increased expression of YKL-40 [33, 34]. Therefore, CHI3L1 gene expression may be regulated by transcription factors such as Sp1 and by DNA methylation status. Our observations with 5-AZA treatment do not support a role for DNA methylation in the expression of YKL-40 in MΦ1. Further studies into methylation status of the promotor of YKL-40, the role of histone modification and microRNAs are needed to define a role of epigenetic mechanisms in the expression of YKL-40 in (lung) macrophages.

The strength of our study is that it describes a thorough evaluation of a novel, potential pro-inflammatory macrophage marker using both in vitro and in vivo approaches. Well-characterized patients with COPD used long-term, randomized, placebo-controlled treatment with ICS. However, we were unable to detect an effect of a randomized treatment with ICS on YKL-40 serum and sputum levels. Nevertheless, our study has some limitations. First, we used in vitro cultured monocyte-derived macrophages from whole blood of healthy subjects that were differentiated towards MΦ1 and MΦ2 instead of lung-derived (e.g. alveolar) macrophages that were differentiated under the influence of the local environment. Since the culture systems do not fully reflect in vitro differentiation of macrophage subsets [35, 36], it needs to be noted that the effect of steroids on lung macrophages may differ from that on in vitro differentiated macrophages. Furthermore, in vivo a heterogeneous and intermediate macrophage population exists [37], which complicates the comparison with in vitro generated MΦ subsets. We therefore cannot formally exclude the possibility that this has contributed to our inability to detect an effect of inhaled corticosteroids on serum and sputum YKL-40 levels. Second, the demethylating agent 5-AZA demonstrated cell toxicity which might have influenced our results. However, we found a dose-dependent inhibition of YKL-40 expression and secretion, suggesting that DNA methylation status may contribute to regulation of YKL-40 expression in MΦ1, which is in line with studies posing that methylation of a part of the CpG island of the CHI3L1 gene is associated with YKL-40 levels [19, 32].

How can we explain that serum and sputum YKL-40 levels of COPD patients were not significantly changed after long-term ICS treatment compared to placebo? This is unexpected since serum YKL-40 levels of rheumatoid arthritis patients rapidly decreased after one week of prednisolone [18]. However, the amount of inhaled fluticasone that reaches the systemic circulation is low [38], which could explain why serum YKL-40 levels did not significantly change with ICS therapy. In addition, lung macrophages in COPD have reduced glucocorticoid sensitivity [39, 40].

Conclusions

YKL-40 is mainly expressed and secreted by MΦ1 and is not further increased by pro-inflammatory stimuli. YKL-40 release is inhibited by dexamethasone in MΦ1 in vitro, whereas long-term treatment of COPD patients with inhaled corticosteroids did not significantly change YKL-40 levels in serum and sputum. This suggests that YKL-40 is a potential marker for in vitro cultured pro-inflammatory macrophages and is not a valuable biomarker in serum and sputum of patients with COPD treated with inhaled corticosteroids.

Abbreviations

5-AZA:

5-AZA-2’-deoxycytidine

BRP-39:

Breast regression protein-39

BSA:

Bovine serum albumin

COPD:

Chronic obstructive pulmonary disease

ELISA:

Enzyme-linked immunosorbent assay

FCS:

Fetal calf serum

FEV1 :

Forced Expiratory Volume in 1 second

GLUCOLD:

Groningen and Leiden Universities Corticosteroids in Obstructive Lung Disease

hCAP:

Human cathelicidin antimicrobial peptide

HC gp-39:

human cartilage glycoprotein-39

ICS:

Inhaled corticosteroids

IL:

Interleukin

LPS:

Lipopolysaccharide

OSM:

Oncostatin M

SNP:

Single-nucleotide polymorphism

TNFα:

Tumour Necrosis Factor-alpha

YKL-40:

Chitinase 3-like-1

References

  1. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006;53:172–209.

    CAS  PubMed  Google Scholar 

  2. Krause SW, Rehli M, Kreutz M, Schwarzfischer L, Paulauskis JD, Andreesen R. Differential screening identifies genetic markers of monocyte to macrophage maturation. J Leukoc Biol. 1996;60:540–5.

    CAS  PubMed  Google Scholar 

  3. Rehli M, Krause SW, Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics. 1997;43:221–5.

    Article  CAS  PubMed  Google Scholar 

  4. Volck B, Price PA, Johansen JS, Sorensen O, Benfield TL, Nielsen HJ, et al. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians. 1998;110:351–60.

    CAS  PubMed  Google Scholar 

  5. Kirkpatrick RB, Emery JG, Connor JR, Dodds R, Lysko PG, Rosenberg M. Induction and expression of human cartilage glycoprotein 39 in rheumatoid inflammatory and peripheral blood monocyte-derived macrophages. Exp Cell Res. 1997;237:46–54.

    Article  CAS  PubMed  Google Scholar 

  6. Rehli M, Niller H-H, Ammon C, Langmann S, Schwarzfischer L, Andreesen R, et al. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem. 2003;278:44058–67.

    Article  CAS  PubMed  Google Scholar 

  7. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a New prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev. 2006;15:194–202.

    Article  CAS  PubMed  Google Scholar 

  8. Lee CG, Da Silva C, Dela Cruz CS, Ahangari F, Ma B, Kang MJ, et al. Role of chitin, chitinase/chitinase-like proteins in inflammation, tissue remodeling, and injury. Annu Rev Physiol. 2011;73:479–501.

    Article  CAS  PubMed  Google Scholar 

  9. Jefri M, Huang Y-N, Huang W-C, Tai C-S, Chen W-L. YKL-40 regulated epithelial-mesenchymal transition and migration/invasion enhancement in non-small cell lung cancer. BMC Cancer. 2015;15:590.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Sakazaki Y, Hoshino T, Takei S, Sawada M, Oda H, Takenaka S, et al. Overexpression of Chitinase 3-Like 1/YKL-40 in Lung-Specific IL-18-Transgenic Mice, Smokers and COPD. PLoS ONE. 2011;6:e24177.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Chupp GL, Lee CG, Jarjour N, Shim YM, Holm CT, He S, et al. A chitinase-like protein in the lung and circulation of patients with severe asthma. N Engl J Med. 2007;357:2016–27.

    Article  CAS  PubMed  Google Scholar 

  12. Otsuka K, Matsumoto H, Niimi A, Muro S, Ito I, Takeda T, et al. Sputum YKL-40 levels and pathophysiology of asthma and chronic obstructive pulmonary disease. Respiration. 2012;83:507–19.

    Article  CAS  PubMed  Google Scholar 

  13. Letuve S, Kozhich A, Arouche N, Grandsaigne M, Reed J, Dombret MC, et al. YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. J Immunol. 2008;181:5167–73.

    Article  CAS  PubMed  Google Scholar 

  14. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet. 2011;378:1015–26.

    Article  CAS  PubMed  Google Scholar 

  15. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005;5:953–64.

    Article  CAS  PubMed  Google Scholar 

  16. Di Rosa M, Malaguarnera G, De Gregorio C, Drago F, Malaguarnera L. Evaluation of CHI3L-1 and CHIT-1 expression in differentiated and polarized macrophages. Inflammation. 2013;36:482–92.

    Article  CAS  PubMed  Google Scholar 

  17. Kzhyshkowska J, Mamidi S, Gratchev A, Kremmer E, Schmuttermaier C, Krusell L, et al. Novel stabilin-1 interacting chitinase-like protein (SI-CLP) is up-regulated in alternatively activated macrophages and secreted via lysosomal pathway. Blood. 2006;107:3221–8.

    Article  CAS  PubMed  Google Scholar 

  18. Johansen JS, Stoltenberg M, Hansen M, Florescu A, Hørslev-Petersen K, Lorenzen I, et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology. 1999;38:618–26.

    Article  CAS  PubMed  Google Scholar 

  19. Ober C, Tan Z, Sun Y, Possick JD, Pan L, Nicolae R, et al. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med. 2008;358:1682–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Michel S, Busato F, Genuneit J, Pekkanen J, Dalphin JC, Riedler J, et al. Farm exposure and time trends in early childhood may influence DNA methylation in genes related to asthma and allergy. Allergy. 2013;68:355–64.

    Article  CAS  PubMed  Google Scholar 

  21. Matsuda A, Asada Y, Takakuwa K, Sugita J, Murakami A, Ebihara N. DNA methylation analysis of human trabecular meshwork cells during Dexamethasone stimulation DNA methylation analysis of trabecular meshwork cells. Invest Ophthalmol Vis Sci. 2015;56:3801–9.

    Article  CAS  PubMed  Google Scholar 

  22. Kagoshima M, Wilcke T, Ito K, Tsaprouni L, Barnes PJ, Punchard N, et al. Glucocorticoid-mediated transrepression is regulated by histone acetylation and DNA methylation. Eur J Pharmacol. 2001;429:327–34.

    Article  CAS  PubMed  Google Scholar 

  23. Verreck FAW, de Boer T, Langenberg DML, van der Zanden L, Ottenhoff THM. Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-{gamma}- and CD40L-mediated costimulation. J Leukoc Biol. 2006;79:285–93.

    Article  CAS  PubMed  Google Scholar 

  24. Wout EFA V ’t, Van Schadewijk A, Savage NDL, Stolk J, Hiemstra PS. a1-antitrypsin production by proinflammatory and antiinflammatory macrophages and dendritic cells. Am J Respir Cell Mol Biol. 2012;46:607–13.

    Article  Google Scholar 

  25. Lapperre TS, Snoeck-Stroband JB, Gosman MM, Jansen DF, Van Schadewijk A, Thiadens HA, et al. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2009;151:517–27.

    Article  PubMed  Google Scholar 

  26. Kunz LIZ, Lapperre TS, Snoeck-Stroband JB, Budulac S, Timens W, van Wijngaarden S, et al. Smoking status and anti-inflammatory macrophages in bronchoalveolar lavage and induced sputum in COPD. Respir Res. 2011;12:34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. in ’t Veen JC, de Gouw HW, Smits HH, Sont JK, Hiemstra PS, Sterk PJ, et al. Repeatability of cellular and soluble markers of inflammation in induced sputum from patients with asthma. Eur Respir J. 1996;9:2441–7.

    Article  PubMed  Google Scholar 

  28. van der Does AM, Beekhuizen H, Ravensbergen B, Vos T, Ottenhoff THM, van Dissel JT, et al. LL-37 directs macrophage differentiation toward macrophages with a proinflammatory signature. J Immunol. 2010;185:1442–9.

    Article  PubMed  Google Scholar 

  29. Hashimoto S, Suzuki T, Dong HY, Yamazaki N, Matsushima K. Serial analysis of gene expression in human monocytes and macrophages. Blood. 1999;94:837–44.

    CAS  PubMed  Google Scholar 

  30. Matsuura H, Hartl D, Kang MJ, Cruz CSD, Koller B, Chupp GL, et al. Role of breast regression protein-39 in the pathogenesis of cigarette smoke-induced inflammation and emphysema. Am J Respir Cell Mol Biol. 2011;44:777–86.

    Article  CAS  PubMed  Google Scholar 

  31. Holmgaard D, Mygind L, Titlestad I, Madsen H, Pedersen S, Johansen J, et al. Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease. BMC Pulm Med. 2013;13:77.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Konradsen JR, James A, Nordlund B, Reinius LE, Söderhäll C, Melén E, et al. The chitinase-like protein YKL-40: a possible biomarker of inflammation and airway remodeling in severe pediatric asthma. J Allergy Clin Immunol. 2013;132:328–35. e325.

    Article  CAS  PubMed  Google Scholar 

  33. Nakano K, Boyle DL, Firestein GS. Regulation of DNA methylation in rheumatoid arthritis synoviocytes. J Immunol. 2013;190:1297–303.

    Article  CAS  PubMed  Google Scholar 

  34. Nakano K, Whitaker JW, Boyle DL, Wang W, Firestein GS. DNA methylome signature in rheumatoid arthritis. Ann Rheum Dis. 2013;72:110–7.

    Article  CAS  PubMed  Google Scholar 

  35. Gordon S, Mantovani A. Diversity and plasticity of mononuclear phagocytes. Eur J Immunol. 2011;41:2470–2.

    Article  CAS  PubMed  Google Scholar 

  36. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122:787–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Hiemstra PS. Altered macrophage function in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2013;10:S180–5.

    Article  PubMed  Google Scholar 

  38. Falcoz C, Oliver R, McDowall JE, Ventresca P, Bye A, Daley-Yates PT. Bioavailability of orally administered micronised fluticasone propionate. Clin Pharmacokinet. 2000;39 Suppl 1:9–15.

    Article  CAS  PubMed  Google Scholar 

  39. Culpitt SV, Rogers DF, Shah P, De Matos C, Russell REK, Donnelly LE, et al. Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167:24–31.

    Article  PubMed  Google Scholar 

  40. Ito K, Lim S, Caramori G, Chung KF, Barnes PJ, Adcock IM. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J. 2001;15:1110–2.

    CAS  PubMed  Google Scholar 

Download references

Financial support

This study was funded by a grant from the Lung Foundation Netherlands (grant number 3.2.08.0032 and 93.96.3), the Netherlands Organization for Scientific Research (NWO) (grant number 940-35-033), GlaxoSmithKline (GSK) of The Netherlands (grant number SCO107656), University Medical Center Groningen and Leiden University Medical Center.

Author information

Author notes

    Authors and Affiliations

    1. Department of Pulmonology, Leiden University Medical Center, Albinusdreef 2, NL-2333, ZA, Leiden, The Netherlands

      L. I. Z. Kunz, E. F. A. van’t Wout, A. van Schadewijk & P. S. Hiemstra

    2. Department of Pulmonology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

      D. S. Postma & H. A. M. Kerstjens

    3. Department of Respiratory Medicine, Academic Medical Center, Amsterdam, The Netherlands

      P. J. Sterk

    Authors
    1. L. I. Z. Kunz
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. E. F. A. van’t Wout
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. A. van Schadewijk
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. D. S. Postma
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. H. A. M. Kerstjens
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. P. J. Sterk
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. P. S. Hiemstra
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to L. I. Z. Kunz.

    Additional information

    Competing interests

    The GLUCOLD study was funded by the Netherlands Organization for Scientific Research (NWO) (grant number 940-35-033), Lung Foundation Netherlands (grant number 93.96.3), GlaxoSmithKline (GSK) of The Netherlands (grant number SCO107656), University Medical Center Groningen and Leiden University Medical Center.

    Authors’ contributions

    LK, EW, AS and PH designed the study and the experiments. EW was responsible for the cell cultures. LK, EW and AS were involved in ELISA, immunocytochemical staining and qPCR. LK performed the sputum inductions, AS was responsible for processing the serum and sputum samples. LK and EW statistically analyzed the data. DP, HK and PS were responsible for the initiation of the GLUCOLD study and recruitment of the patients. LK, EW and PH drafted the manuscript. All authors have read, revised and approved the submission of the final manuscript.

    L. I. Z. Kunz and E. F. A. van’t Wout contributed equally to this work.

    Rights and permissions

    Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Kunz, L.I.Z., van’t Wout, E.F.A., van Schadewijk, A. et al. Regulation of YKL-40 expression by corticosteroids: effect on pro-inflammatory macrophages in vitro and its modulation in COPD in vivo. Respir Res 16, 154 (2015). https://doi.org/10.1186/s12931-015-0314-3

    Download citation

    • Received:

    • Accepted:

    • Published:

    • DOI: https://doi.org/10.1186/s12931-015-0314-3

    Keywords

    Respiratory Research

    ISSN: 1465-993X

    Contact us